drugset / Trial / NCT04148183

Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients.

NCT04148183

RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the effect of insulin sensitizing drugs (metformin and rosiglitazone) over glucose homeostasis (GH) in no diabetic metabolic syndrome individuals. A randomized blinded clinical trial did in patients with metabolic syndrome (n=30), without diabetes. Prior to detailed information and signature of informed consent by patients were done three treatment groups by randomized technique; a) Placebo, b) Metformin (850 mg/day), c) Rosiglitazone (4 mg/day), treatment was administered for 8 weeks. GH was measured before and after treatment using oral glucose tolerance test (OGTT), and IR-index (Homeostatic Model). Determination was performed on weight, size, body mass index, plicometry, blood pressure, fasting glucose levels, triglycerides, HDL-cholesterol and insulin.

Timeline

Start
2004-01-01
Primary completion
2005-01-01
Completion
2009-01-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 850 mg
Subject Rosiglitazone Small molecule 4 mg

Indications

No indication recorded.